Exploring gaps in GLP-1 research, care, and coverage

GLP-1 drugs, like Ozempic, Wegovy, and Zepbound, have gained attention for their significant health impacts and anti-obesity effects. However, there continues to be a lot of unknowns surrounding these medications, their long-term impacts, and access.

Featuring: Dr. Lydia Alexander, an obesity medicine specialist, lifestyle specialist, president of the Obesity Medicine Association (OMA), Chief Medical Officer at Enara, and a medical chef.

In today’s episode, we’ll cover

• The significant progress made in GLP-1 research, care delivery, and insurance coverage
• Filling research gaps in GLP-1 care through longitudinal studies examining long-term medication effects and potential adverse reactions
• Tips for providers managing patients on GLP-1 medications and patient-focused approaches to obesity management

And more!

To watch video clips from our podcast, subscribe to our YouTube channel, @Healthcare Strategies

Resources:

• Are compounded “DIY” peptides the answer to the GLP-1 shortage?
• Exploring FDA-approved GLP-1 receptor agonists
• Addressing muscle loss associated with GLP-1 medication use